

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 59413

Title: Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report

Reviewer's code: 01552044

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor, Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: China

Manuscript submission date: 2020-10-22

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2020-11-30 12:49

Reviewer performed review: 2020-12-02 11:20

Review time: 1 Day and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting case report of potential interest to the readers of the Journal. The case is well presented, imaging is of good quality and I recommend this manuscript be accepted as is

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 59413

Title: Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report

Reviewer's code: 03544596

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: China

Manuscript submission date: 2020-10-22

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2020-12-10 06:11

Reviewer performed review: 2020-12-15 08:05

Review time: 5 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Thanks to the authors for this case report. This agent is mostly used in the treatment of Crohn's disease. This case report is important as it reminds patients receiving Infliximab to closely monitor.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 59413

Title: Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report

Reviewer's code: 04091933

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Senior Researcher

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2020-10-22

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2020-12-10 15:18

Reviewer performed review: 2020-12-17 20:03

Review time: 7 Days and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

IBD and colorectal cancer with a worldwide increasing incidence and prevalence, are important gastroenterological pathologies that require special attention to patient management. Despite the fact that the therapeutic agents, including biologicals, are highly effective in the management of patients with IBD, the safety and long-term effects of biologic therapy are not fully understood. Infliximab has been used for over 20 years in clinical practice and is considered a relatively safe drug, although interference with the patient's immune system a priori can lead to serious infections and malignancies. The presented case of well-differentiated adenocarcinoma in a patient with IBD after infliximab therapy is interesting and clinically important, since it shows the possibility of rapid growth and progression of neoplasia, possibly induced by biological therapy. This case can really increase the attention to the management of IBD patients with a focus on careful diagnosis and regular/continuous monitoring of patients on biologicals. The case is well described and illustrated and can be recommended for publication. References are relevant, fully consistent with the topic of the manuscript and without self-citation.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 59413

Title: Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report

Reviewer's code: 03544596

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: China

Manuscript submission date: 2020-10-22

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2021-01-18 06:34

Reviewer performed review: 2021-01-18 06:52

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Thanks to the authors for this good and interesting case report. Infliximab is effective in the management of patients with IBD. This agent is mostly used in the treatment of Crohn's disease. Malignancy may be induced by Infliximab. Because of that, this case report is important as it reminds patients receiving Infliximab to closely monitor.